Nasdaq Carm News Today

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) rose 0.4% on Tuesday . The stock traded as high as $2.60 and last traded at $2.54. Approximately 233,084 shares changed hands during trading, an increase of 72% from the average daily volume of 135,874 shares. The stock had previously closed at $2.53. Wall Street […]

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has received a consensus recommendation of “Buy” from the five brokerages that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year […]

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has been assigned an average recommendation of “Buy” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock […]

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,580,000 shares, a decrease of 8.5% from the August 31st total of 2,820,000 shares. Based on an average trading volume of 234,300 shares, the short-interest ratio is currently 11.0 […]

Carisma Therapeutics (NASDAQ:CARM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $11.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 121.33% from the stock’s previous close. Other analysts have also […]

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) had its price target boosted by equities research analysts at HC Wainwright from $10.00 to $11.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 74.33% from […]

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) and Innovus Pharmaceuticals (OTCMKTS:INNVD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Profitability This table compares Carisma Therapeutics and […]

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 2,450,000 shares, an increase of 7.9% from the June 30th total of 2,270,000 shares. Approximately 13.3% of the shares of the company are […]

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 2,450,000 shares, an increase of 7.9% from the June 30th total of 2,270,000 shares. Based on an average trading volume of 314,700 shares, the days-to-cover ratio is currently 7.8 […]

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Rating) was the target of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 521,900 shares, a drop of 18.1% from the May 15th total of 636,900 shares. Based on an average daily trading volume, of 179,900 shares, […]